Development and Assessment of Two Highly Pathogenic Avian Influenza(HPAI) H5N6 Candidate Vaccine Viruses for Pandemic Preparedness  

作　　者：LIU Li Qi LI Zi JIAO Ming LU Jian ZHOU Jian Fang LI Xi Yan LIU Jia GUO Jun Feng XIAO Ning ZHAO Xiang WANG Da Yan 

机构地区：[1]Chinese National Influenza Center,National Institute for Viral Disease Control and Prevention,China CDC,Beijing 102206,China

出　　处：《Biomedical and Environmental Sciences》2020年第9期670-679,共10页生物医学与环境科学（英文版）

基　　金：This study was supported by the National Major Science and Technology Project for Control and Prevention of Major Infectious Diseases in China[No.2018ZX10711001,2018ZX10305409-004-002];Emergency Prevention and Control Project of Ministry of Science and Technology of China[No.10600100000015001206].

摘　　要：Objective In China, 24 cases of human infection with highly pathogenic avian influenza(HPAI) H5 N6 virus have been confirmed since the first confirmed case in 2014. Therefore, we developed and assessed two H5 N6 candidate vaccine viruses(CVVs).Methods In accordance with the World Health Organization(WHO) recommendations, we constructed two reassortant viruses using reverse genetics(RG) technology to match the two different epidemic H5 N6 viruses. We performed complete genome sequencing to determine the genetic stability. We assessed the growth ability of the studied viruses in MDCK cells and conducted a hemagglutination inhibition assay to analyze their antigenicity. Pathogenicity attenuation was also evaluated in vitro and in vivo.Results The results showed that no mutations occurred in hemagglutinin or neuraminidase, and both CVVs retained their original antigenicity. The replication capacity of the two CVVs reached a level similar to that of A/Puerto Rico/8/34 in MDCK cells. The two CVVs showed low pathogenicity in vitro and in vivo, which are in line with the WHO requirements for CVVs.Conclusion We obtained two genetically stable CVVs of HPAI H5N6 with high growth characteristics,which may aid in our preparedness for a potential H5N6 pandemic.

关 键 词：Highly pathogenic avian influenza H5N6 virus Genetic stability Candidate vaccine virus Reverse genetic technology 

分 类 号：R392[医药卫生—免疫学]